the effect of erythropoietin administration on the serum level of ykl-40, pro-bnp and il-6 in coronary surgery patients

Cardiopulmonary bypass and aortic clamping evokes the obligatory global myocardialischemia and dysfunction with a significant inflammatory response. the discrepancy aboutcardioprotective effects of erythropoietin still exist. the aim of this study was to assess the clinicalimmunomodulatory effects of erythropoietin (epo) on serum inflammatory biomarkers (ykl-40, il-6) and cardiac biomarkers, (pro-bnp, ck-mb and troponin). in this randomized doubleblind clinical trial, 132 patients admitted for elective coronary surgery with cardiopulmonarybypass (cpb) were randomly assigned in one of three groups: 1-group epo-a (n = 35) infusionof 300 iu/kg epo after anesthesia induction and before undergoing cpb; 2- group epo-cpb(n = 31) the same intervention during cpb; 3- placebo group (n = 66) saline infusion in thesame volume. cardiac enzymes and serum biomarkers were measured at intervals. there wasa sharp increase in serum ykl-40 with a 24 h delay after cpb in all groups without significantdifference. the increase in serum il-6 was significant in epo-cpb group compared with bothother groups (p = 0.001 and p = 0.001, respectively). serum pro-bnp reached maximum level24 h after operation in all groups; in group a significantly less than others (p = 0.008). ckmbincreased significantly in all groups (p < 0.001), less prominently in cpb-a group (p =0.03). epo administration before induced ischemia may be cardioprotective in terms of cardiacbiomarkers in patients undergoing cabg with cpb.